Comparative Pharmacology
Head-to-head clinical analysis: DICHLORPHENAMIDE versus KEVEYIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DICHLORPHENAMIDE versus KEVEYIS.
DICHLORPHENAMIDE vs KEVEYIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dichlorphenamide is a carbonic anhydrase inhibitor. It inhibits the enzyme carbonic anhydrase in the proximal renal tubule, reducing reabsorption of bicarbonate, leading to metabolic acidosis, and decreasing intraocular pressure by reducing aqueous humor formation.
Keveyis (dichlorphenamide) is a carbonic anhydrase inhibitor. It reduces the frequency of attacks in primary hyperkalemic periodic paralysis by decreasing intracellular pH, which stabilizes muscle cell membranes and reduces potassium efflux from muscle cells.
25-50 mg orally twice daily.
50 mg orally twice daily with food; may increase to 100 mg twice daily after 2 weeks if needed.
None Documented
None Documented
Terminal elimination half-life of 2-4 hours; increased in renal impairment, up to 12-24 hours in severe insufficiency.
Terminal elimination half-life: 15–20 hours following a single oral dose; at steady state, half-life 42–80 hours (mean ~60 h) due to dose-dependent kinetics.
Primarily renal via tubular secretion; 50-70% excreted unchanged in urine; minor biliary/fecal elimination (<20%).
Primarily renal: unchanged drug accounts for ~82% of dose in urine; fecal excretion <5%; minor hepatic metabolism.
Category C
Category C
Carbonic Anhydrase Inhibitor
Carbonic Anhydrase Inhibitor